相对年轻的心力衰竭的特征与保存的喷射分数:PurSuit-HFpEF注册表
Masami Nishino1, Yasuyuki Egami2, Ayako Sugino2
1Division of Cardiology, Osaka Rosai Hospital, 3-1179 Nagasonecho, Kita-Ku, Sakai, Osaka, 591-8025, Japan. mnishino@osakah.johas.go.jp.
Heart and vessels
|April 15, 2025
概括
年轻患者心力衰竭与保存的喷射分数 (HFpEF) 是罕见的,经常呈现肥胖和吸烟. 虽然HF再接收率与老年人相似,但在出院时使用特定药物可能会减少年轻HFpEF患者的再接收率.
科学领域:
- 心脏病学 心脏病学
- 内部医学 内部医学
- 老年病的医生 老年病的医生
背景情况:
- 保持喷射分数 (HFpEF) 的心力衰竭主要影响老年人群.
- 关于年轻HFpEF患者的特征和结果的研究有限.
研究的目的:
- 为了识别年轻HFpEF患者的独特特征.
- 为了比较年轻和年长的HFpEF队列之间的全因死亡率和心力衰竭再入院 (HFR).
- 为了确定年轻HFpEF患者中与HFR相关的排出因子.
主要方法:
- 对PURSUIT-HFpEF注册表的分析,将患者分为年轻 (≤65岁) 和年长的HFpEF组.
- 两组的人口,临床和结果数据的比较.
- 多变量考克斯比例危险分析,以确定年轻HFpEF患者中HFR的预测因素.
主要成果:
- 年轻的HFpEF患者占队列的4.1%,体质指数和吸烟率较高,但高血压患病率较低.
- 在年轻和年长的HFpEF组之间没有观察到HFR的显著差异.
- 在较年轻的HFpEF组中,全因死亡率明显较低 (p < 0.001).
- ангиотензин转化酶抑制剂 (ACEI) 或 ангиотензинII受体阻断剂 (ARB) 的使用与HFR相反相关 (p = 0.004).
- 在较年轻的HFpEF患者中,矿物质皮质类受体抗剂 (MRA) 的使用与HFR (p = 0.007) 有积极的相关性.
结论:
- 年轻人HFpEF不常见,肥胖和吸烟是关键可修改的风险因素.
- 在年轻和年长的HFpEF患者中,HFR率是可比的.
- 在较年轻的HFpEF患者中,注射ACEI/ARB和避免MRA可能会降低HFR.
相关概念视频
01:17Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
01:26Imbalances in Cardiac Output
1.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
01:26Heart Failure Drugs: Inotropic Agents
481
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
481
01:22Heart Failure Drugs: β-Blockers
300
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
300
01:22Heart Failure Drugs: Diuretics
313
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
313
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
356
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
356